Asia Pacific Industrial Gases Market Size, Share & Trends, 2033
The Asia Pacific industrial gases market, valued at USD 25.39 billion in 2024, is projected to reach USD 43.01 billion by 2033, growing at a CAGR of 6.03%. Key drivers include the expanding steel and metal fabrication industries and increasing demand in healthcare, while high transportation costs and stringent environmental regulations act as restraints. Significant opportunities lie in renewable energy solutions, particularly hydrogen fuel cells and carbon capture technologies, and the booming electronics manufacturing sector.
GE Just Hit Another Record. No One Noticed.
General Electric, though now split into three distinct companies (GE Aerospace, GE Vernova, and GE HealthCare Technologies), has collectively reached a new record value. This achievement highlights the successful restructuring of the historic company founded by Thomas Edison. Despite its significant milestone, the article suggests this record has gone unnoticed by many.
GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio
GE HealthCare (GEHC) has received FDA 510(k) clearance for three new magnetic resonance (MR) innovations: SIGNA Sprint with Freelium, SIGNA Bolt, and SIGNA One. These next-generation MRI systems are designed to enhance efficiency, sustainability, and diagnostic accuracy, addressing rising demand and workforce constraints in radiology. The clearances reinforce GEHC's leadership in precision imaging and align with broader healthcare trends towards sustainability, automation, and operational efficiency.
GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio
GE HealthCare has secured FDA 510(k) clearance for three new MR innovations: SIGNA Sprint with Freelium, a 1.5T sealed MRI system; SIGNA Bolt, an advanced 3T MRI scanner; and SIGNA One, an AI-enabled workflow ecosystem. These advancements aim to address rising imaging volumes, workforce constraints, and sustainability needs in the radiology market. The new portfolio enhances efficiency, diagnostic accuracy, and sustainability, solidifying GE HealthCare's leadership in precision imaging and supporting long-term revenue growth.
Boston Scientific Stock is Down 20% This Year. Here Is What Investors Need to Know Before March 28
Boston Scientific (BSX) stock has declined significantly, trading near its 52-week low after a steep single-day drop due to Q4 EP sales missing estimates. Despite solid overall Q4 results, the market focused on perceived decelerations in key growth drivers, leading to analyst price target cuts. Investors are now looking to the CHAMPION trial readout on March 28 and the eventual Penumbra close as critical near-term catalysts that could reframe the company's growth story and potentially unlock significant upside from its currently undervalued price.
Regeneron Stock: Here’s Why Four Expected FDA Approvals Could Push its 36% Rally Even Higher
Regeneron Pharmaceuticals (REGN) is showing strong performance, nearing its 52-week high, driven by an anticipated four FDA approvals in 2026 and a robust pipeline. The company's recent BLA acceptance for garetosmab for FOP, with striking Phase 3 data, highlights its transition from a two-product company to a diversified late-stage platform. Analysts project continued revenue and EPS growth, with TIKR's valuation model suggesting significant upside, contingent on key pipeline readouts and approvals.
GE HealthCare's SIGNA MRI Portfolio Granted FDA Clearance
GE HealthCare has received FDA clearance for three new MRI innovations: SIGNA Sprint with Freelium (a 1.5T sealed magnet MRI system), SIGNA Bolt (an advanced 3T MRI scanner), and SIGNA One (an AI-driven workflow ecosystem). These technologies aim to address challenges in radiology such as increasing demand, workforce burnout, and sustainability. The new systems are designed to enhance precision imaging, improve clinical efficiency, and provide smarter, faster, and more sustainable imaging solutions.
Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026
Abbott Laboratories (ABT) shares are trading around $112, reflecting a 16% pullback from recent highs due to a FreeStyle Libre 3 sensor recall and weakness in the Nutrition segment. Despite these headwinds, the company's Medical Devices segment remains strong, and upcoming catalysts including the Exact Sciences acquisition and the Volt PFA launch have analysts projecting a mean price target of $133.39.
nVent Adds Mellinda Devese as Chief Supply Chain Officer
nVent Electric plc (NYSE: NVT) has appointed Mellinda Devese as Executive Vice President and Chief Supply Chain Officer, effective March 16, 2026. Devese joins from GE HealthCare and will oversee global manufacturing, procurement, and logistics to support nVent's growth in electrification and data center infrastructure.
nVent Adds Mellinda Devese as Chief Supply Chain Officer
nVent Electric plc announced the appointment of Mellinda Devese as Executive Vice President and Chief Supply Chain Officer, effective March 16, 2026. Devese will be responsible for nVent’s global, end-to-end integrated supply chain operations, reporting directly to nVent Chair and CEO Beth Wozniak. Her role will focus on driving growth, operational efficiencies, and customer and supplier experience, leveraging her extensive background from GE HealthCare, Whirlpool, and Eaton Corporations.
nVent Adds Mellinda Devese as Chief Supply Chain Officer
nVent Electric plc announced the appointment of Mellinda Devese as Executive Vice President and Chief Supply Chain Officer, effective March 16, 2026. Devese will be responsible for leading nVent's global, end-to-end integrated supply chain and is expected to drive growth, transformation, and operational excellence. She brings extensive experience from GE HealthCare, Whirlpool, and Eaton Corporations.
GE HealthCare achieves MRI portfolio milestone with FDA clearances for next-generation SIGNA MRI tec
GE HealthCare has received FDA 510(k) clearance for three new Magnetic Resonance (MR) innovations: SIGNA™ Sprint with Freelium™ (a 1.5T sealed magnet MRI system), SIGNA™ Bolt (an advanced 3T MRI scanner), and SIGNA™ One (an AI-driven workflow ecosystem). These new technologies aim to address challenges in radiology such as rising demand, workforce burnout, and sustainability concerns by enhancing precision imaging, clinical efficiency, and operational autonomy. The clearances mark a significant step in GE HealthCare's strategy to innovate and differentiate its MR portfolio, providing smarter, faster, and more sustainable imaging solutions.
Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views?
This article analyzes whether Intuitive Surgical (ISRG) is a worthwhile investment based on Wall Street's bullish views. It highlights that while analysts give ISRG an average brokerage recommendation of 1.77 (approximating Strong Buy), investors should be wary of inherent biases in these ratings. The piece suggests using the Zacks Rank, a proprietary stock rating tool based on earnings estimate revisions, as a more reliable indicator for investment decisions.
GE HealthCare wins FDA nod for next-gen Signa MRI tech
GE HealthCare has secured FDA clearance for three new MRI offerings: Signa Sprint with Freelium, Signa Bolt, and Signa One. These innovations aim to address radiology challenges by providing smarter, faster, and more sustainable imaging solutions. The new technologies include helium-free MRI, advanced 3T systems, and an AI-driven ecosystem for workflow efficiency and improved patient care.
GE HealthCare Wins 3 FDA Nods for Next-Gen SIGNA MRI Tech
GE HealthCare has received three FDA 510(k) clearances for new magnetic resonance (MR) technologies: SIGNA Sprint with Freelium (a 1.5T sealed magnet MRI system), SIGNA Bolt (a 3T MRI scanner), and SIGNA One (an AI-driven workflow ecosystem). These innovations aim to address rising procedural demand, increase efficiency, and sustainability in radiology by providing smarter, faster, and more consistent imaging solutions. The company said these advancements will help meet the growing challenges faced by healthcare providers, including an aging population, workforce burnout, and increasing disease incidences.
MRI scanners that sip helium and power: inside GE's new FDA-cleared lineup
GE HealthCare has received FDA 510(k) clearance for three new magnetic resonance (MR) innovations: SIGNA Sprint with Freelium, a 1.5T sealed magnet MRI system; SIGNA Bolt, an advanced 3T MRI scanner; and SIGNA One, an AI-driven workflow ecosystem. These technologies are designed to address the increasing demand for MRI procedures, workforce burnout, and sustainability concerns by offering enhanced precision imaging, greater efficiency, and reduced power and helium consumption. The advancements aim to expand access to high-quality MR imaging and elevate care standards across various clinical settings.
Sleep Aids: Trends, Technologies and Global Markets to 2030 Featuring Key Players Fisher & Paykel Healthcare, ResMed, Philips, Alphabet, Apple and More
The global sleep aid technology market is projected to grow from $103.5 billion in 2025 to $136 billion by 2030, driven by an increase in sleep disorders, advancements in technology, and a rising focus on wellness. Key players like ResMed, Philips, Apple, and Alphabet are leading innovation with a focus on personalized and effective sleep solutions. The market analysis includes segmentation by product type, end-user, sleep disorder, and region, providing a comprehensive overview for stakeholders.
GE Aerospace Readies Takeoff With Its 'AI Wingmate' In Tow
GE Aerospace (GE) has significantly soared since its split from General Electric in April 2024, showing a 147% increase in stock value. The company is poised for another record high breakout, especially after receiving a boost this week from United Airlines. This success highlights GE Aerospace's strong performance as a pure-play aviation giant.
GE HealthCare and BARDA outlay $35m to expand AI ultrasound development contract
GE HealthCare and BARDA have expanded their contract by $35 million to further develop AI-powered ultrasound systems. This expansion focuses on enhancing imaging for trauma assessment and mass casualty incidents, aiming to improve diagnostic speed and reduce reliance on expert users, especially in challenging field environments. The initiative builds on a previous $44 million agreement and seeks to generate clinical evidence for next-generation point-of-care ultrasound technology with new AI applications.
Medtronic nets FDA clearance for robotic spine system
Medtronic has received FDA clearance for its new Stealth AXiS surgical system, a next-generation robotic platform for spine surgery. This system integrates AI-based planning, real-time navigation, and robotic assistance, building on Medtronic's acquisition of Mazor Robotics. It is designed for use in both hospitals and ambulatory surgical centers and aims to increase Medtronic's market share in the cranial and spinal technologies sector.
GE HealthCare, BARDA ink $35M expansion to AI-enabled imaging deal
GE HealthCare has secured a $35 million contract expansion from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to further develop AI-enabled ultrasound technology for trauma care. This builds on a prior 2023 agreement and aims to create tools that allow non-expert users to more easily and quickly diagnose patients, particularly in demanding environments. The expanded project focuses on improving assessments of lung pathologies and intra-abdominal injuries, with GE HealthCare co-funding the initiative, although BARDA provides the majority of the funds.
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
Glaukos Corporation (GKOS) reported a Q4 2025 adjusted loss of 28 cents per share, missing estimates, despite revenues of $143.1 million surpassing expectations. The company provided optimistic 2026 guidance, expecting net sales between $600-$620 million, driven by strong adoption of iDose TR and the launch of Epioxa. Glaukos anticipates continued growth with ongoing investment in new platforms and pipeline developments, positioning itself for double-digit revenue expansion.
NEOS Investment Management LLC Purchases 80,606 Shares of GE HealthCare Technologies Inc. $GEHC
NEOS Investment Management LLC increased its stake in GE HealthCare Technologies Inc. by 70.1% in the third quarter, acquiring 80,606 shares to bring its total holdings to 195,597 shares valued at $14.69 million. Several other hedge funds also adjusted their positions in GEHC. Analysts generally rate the stock as "Hold" with a consensus target price of $92.50, although some firms have recently raised price targets and maintained "Buy" or "Overweight" ratings.
Healthcare Biometrics Market to Grow at 15% CAGR by 2031; North
The global Healthcare Biometrics Market is projected to grow at a Compound Annual Growth Rate (CAGR) of 15% between 2024 and 2031, primarily driven by the increasing need for fraud prevention and enhanced patient privacy and safety. North America currently leads the market with a 40% share, attributed to its advanced healthcare infrastructure and early adoption of digital health solutions. Key players in this market include Zkteco, Inc, Thales Group, Bio-Key International Inc, and Crossmatch Technologies Inc.
Cardiovascular Devices Market Booming Rapidly from 2026 to 2033
The Cardiovascular Devices market is projected to grow significantly, from USD 66,420.8 million in 2025 to USD 1,12,366.1 million by 2032, at a CAGR of 7.8%. A new report from Coherent Market Insights details this growth, analyzing market dynamics, key players like Livanova PLC and Medtronic PLC, and regional trends, with forecasts extending to 2033. The study aims to provide stakeholders with insights into market opportunities and challenges across various segments.
Vanguard Group Inc. Lowers Position in GE HealthCare Technologies Inc. $GEHC
Vanguard Group Inc. reduced its stake in GE HealthCare Technologies Inc. by 0.2% in the third quarter, selling 99,049 shares but retaining over 52 million shares valued at approximately $3.91 billion. Institutional investors collectively hold about 82.06% of the company's stock. GE HealthCare reported strong quarterly earnings, beating expectations, and announced a new dividend, with analysts maintaining a "Hold" rating and an average price target of $92.50.
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications
GE HealthCare (GEHC) saw its stock price rise after the FDA approved expanded indications for its diagnostic agent Vizamyl. The approval now allows Vizamyl to help estimate the brain amyloid plaque density in patients undergoing evaluation for Alzheimer's disease and other cognitive impairments. This makes it the first diagnostic tool approved for assessing amyloid plaque density with a four-tier classification system.
Europe Diagnostic Imaging Market is expected to reach US$ 12.32
The Europe Diagnostic Imaging Market is projected to grow from US$ 7.6 billion in 2023 to US$ 12.32 billion by 2031, exhibiting a CAGR of 6.2%. This growth is attributed to rising chronic diseases, aging populations, technological advancements, and a demand for early medical diagnosis. Key players in this market include Siemens Healthineers AG, GE Healthcare, Hitachi Medical Corporation, Hologic Inc., and Philips Healthcare.
Medtronic completes first U.S. cases with Hugo
Medtronic has announced the successful completion of the first U.S. commercial cases utilizing its Hugo soft-tissue robotic surgery system. Dr. Jihad Kaouk of Cleveland Clinic performed a robotic-assisted prostatectomy, marking a significant step following FDA clearance for urologic procedures late last year. This move positions Medtronic to challenge Intuitive's longstanding dominance in the U.S. soft-tissue surgical robotics market, with CEO Geoff Martha expressing optimism about future expansions into additional indications.
Assessing GE HealthCare Technologies (GEHC) Valuation After Recent Share Price Swings
GE HealthCare Technologies (GEHC) has experienced recent stock fluctuations, with a 7% decline over one month and an 8% gain over three months, leading to questions about its valuation. Currently trading at US$78.65, analysts suggest a fair value of $93.25, indicating it might be undervalued. This assessment depends on factors like easing tariffs and China policy risks, as well as maintaining market share against competitors.
Looking Into GE HealthCare Technologies Inc's Recent Short Interest
GE HealthCare Technologies Inc (NYSE: GEHC) has seen a 7.67% decrease in its short interest, now standing at 9.97 million shares, which is 2.89% of its float. This reduction in short interest could indicate a more bullish sentiment from investors. The company's short interest is also lower than the average of its peer group, which is 4.52%.
GE HealthCare Technologies Inc. stock rises Tuesday, outperforms market
GE HealthCare Technologies Inc. (GEHC) saw its stock rise by 1.58% to $81.61 on Tuesday. This performance outperformed the broader market, with the S&P 500 Index rising 0.10% and the Dow Jones Industrial Average rising 0.07%. This marked the company's second consecutive day of gains.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx announced positive clinical validation data for AlloHeme, a new blood-based monitoring test designed to predict relapses in AML and MDS patients following allogeneic hematopoietic cell transplant. The ACROBAT study demonstrated AlloHeme's high diagnostic accuracy and ability to detect relapse earlier than traditional methods, supporting its commercialization beginning in 2027 as part of CareDx’s Transplant+ strategy. This advancement positions CareDx for growth in the cell therapy and hematologic oncology markets, expanding its precision medicine portfolio.
GE HealthCare, BARDA expand collab with $35M AI-powered ultrasound expansion
GE HealthCare announced a $35 million expansion of its existing contract with BARDA to develop AI-powered ultrasound solutions. The collaboration aims to enhance diagnostic speed, reduce operator dependency, and improve trauma assessment, especially for mass casualty incidents, by creating new automated tools for lung pathologies and intra-abdominal injuries. GE HealthCare will also focus on developing robust point-of-care ultrasound solutions for challenging environments, building on its experience with systems like the Venue.
US backs $35M AI ultrasound push to speed trauma diagnosis
GE HealthCare announced an approximately $35 million expansion of its contract with BARDA to advance AI-powered ultrasound solutions for trauma care and emergency preparedness. This funding will support the development of AI-powered tools to enhance diagnostic speed and reduce operator dependency, especially in challenging environments like mass casualty incidents. The collaboration aims to improve detection of injuries and lung pathologies, and will involve clinicians to generate evidence and gather real-world feedback on the technology.
Danaher to buy Masimo for $9.9 billion
Danaher will acquire pulse oximeter maker Masimo in a $9.9 billion deal, aiming to strengthen its diagnostics portfolio. This acquisition marks Danaher's largest deal since 2023 and is expected to expand its presence in patient-monitoring products, complementing its existing medical devices. The deal is anticipated to close by the second half of 2026 and contribute to Danaher's adjusted diluted net earnings per share.
Smart Hospitals Market to See Thriving Worldwide |Medtronic
The Smart Hospitals Market is projected to grow significantly, reaching USD 222.92 billion by 2032 with a CAGR of 20.7% from 2025. This growth is driven by rapid innovation and investment across various components and technologies. The report details market segmentation, key players like Medtronic Plc and Philips N.V., regional coverage, and provides strategic insights for stakeholders.
How to Play Hologic Stock Post Q1 Earnings and Progress on Buyout?
Hologic's $18.3 billion private takeover by Blackstone and TPG is nearing completion, with shareholder approval and a recent regulatory nod from China. Despite this progress, Hologic reported mixed Q1 fiscal 2026 results, missing analyst forecasts for both revenue and earnings, and its stock is trading near the buyout cash price, limiting upside for current shareholders. Zacks Investment Research recommends that investors consider exiting their positions due to minimal upside potential and premium valuation.
How to Play Hologic Stock Post Q1 Earnings and Progress on Buyout?
Hologic's $18.3 billion private takeover by Blackstone and TPG is nearing completion, with shareholder approval and regulatory clearance from China. Despite missing Q1 fiscal 2026 revenue and earnings forecasts, the company's Aptima HPV Assay recently received FDA approval for primary screening. Given the minimal upside from the buyout price and underperformance compared to peers, Zacks Investment Research suggests investors consider exiting their positions.
BioNano Genomics Symposium to Spotlight Key Technology Advancements
BioNano Genomics is preparing for its annual symposium, which will highlight advancements in its optical genome mapping (OGM) technology, particularly its applications in oncology and genetic disease research. The event aims to demonstrate OGM's ability to detect complex genomic alterations often missed by conventional methods, driving broader integration into clinical practice. Investors are also looking forward to the supervisory board meeting on March 31, 2026, for the 2025 financial statements.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx recently announced positive clinical validation data for its AlloHeme blood test, designed to predict relapses in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplant (HCT). The ACROBAT study demonstrated AlloHeme's high sensitivity and specificity, detecting relapses earlier than standard methods. This development strengthens CareDx's expansion into cell therapy and hematologic oncology, with commercialization planned for 2027.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx recently announced positive clinical validation data for AlloHeme, a next-generation blood-based monitoring test designed to predict relapses in patients with AML and MDS following HCT. The ACROBAT study demonstrated AlloHeme's high diagnostic accuracy and ability to detect relapse earlier than standard methods, supporting the company's expansion into cell therapy and hematologic oncology. CareDx plans a phased U.S. rollout for AlloHeme, with commercialization expected by 2027.
How to Play Hologic Stock Post Q1 Earnings and Progress on Buyout?
Hologic's $18.3 billion takeover by Blackstone and TPG is nearing completion after shareholders approved the deal and China's SAMR gave its regulatory nod. Despite this progress, Hologic reported disappointing Q1 fiscal 2026 earnings, missing top and bottom-line forecasts. With the stock price close to the buyout offer and limited upside, analysts suggest investors might consider exiting their positions, as tariffs have impacted profitability and recent price performance has been suboptimal compared to peers.
Todd Asset Management LLC Increases Stock Position in GE HealthCare Technologies Inc. $GEHC
Todd Asset Management LLC significantly increased its stake in GE HealthCare Technologies Inc. during Q3, now owning 478,961 shares valued at approximately $35.97 million. This move is part of a broader trend where institutional investors hold 82.06% of the company's stock, with other firms also boosting their positions. GE HealthCare has demonstrated solid financial performance, exceeding quarterly expectations and providing optimistic FY2026 guidance, while analysts maintain a "Hold" rating with an average target price of $92.50.
GE HealthCare Technologies Inc. (GEHC) Stock Analysis: Exploring a 16% Potential Upside with Robust Revenue Growth
GE HealthCare Technologies Inc. (GEHC) operates in the medical devices industry with a significant market capitalization of $36.61 billion. The company shows robust financial health, including substantial revenue growth and free cash flow, and analysts project a potential 16.07% upside for its stock. With a strong presence across various healthcare segments and an optimistic outlook from analysts, GEHC is positioned as a compelling opportunity for growth-oriented investors in the evolving medical technology landscape.
Coronation Fund Managers Ltd. Sells 12,847 Shares of GE HealthCare Technologies Inc. $GEHC
Coronation Fund Managers Ltd. reduced its stake in GE HealthCare Technologies Inc. by 3.8% in the third quarter, selling 12,847 shares. The fund now holds 329,700 shares valued at $24.76 million, making GE HealthCare its 22nd largest holding. The article also details GE HealthCare's recent financial performance, including a quarterly beat on EPS and revenue, FY2026 guidance, and institutional ownership, alongside analyst ratings and price targets.
GE HealthCare Technologies Inc. (GEHC) Expands Healthcare Technology Offerings
GE HealthCare Technologies Inc. (GEHC) has expanded its healthcare technology offerings with the US launch of ReadyFix, a remote fleet management solution for medical devices. This new system aims to reduce device disruptions and downtime by enabling remote diagnostics, repair, and maintenance for connected medical equipment, particularly ECG workstations. The company previously declared a Q1 2026 cash dividend of $0.035 per share, unchanged from Q4 2025.
GE HealthCare Technologies Inc. (GEHC) Expands Healthcare Technology Offerings
GE HealthCare Technologies Inc. (GEHC) has announced a Q1 2026 cash dividend of $0.035 per share and launched ReadyFix, a remote fleet management solution for medical devices. ReadyFix aims to improve uptime and streamline maintenance for healthcare systems by enabling remote diagnostics, repair, and software updates for connected medical devices. The company emphasizes the solution's role in reducing device disruptions, particularly for critical cardiac care equipment, to address the growing complexity of hospital device fleets.
GE HealthCare Technologies Inc. (NASDAQ:GEHC) Plans Quarterly Dividend of $0.04
GE HealthCare Technologies Inc. (NASDAQ:GEHC) has announced a quarterly dividend of $0.035 per share, payable on May 15th to shareholders of record on April 3rd, with an ex-dividend date of April 2nd. This dividend represents an annualized yield of 0.2% and is well-covered by earnings, with a payout ratio of 3.0%. The company recently exceeded quarterly earnings expectations, reporting an EPS of $1.44 against a consensus of $1.40 and revenue of $5.70 billion, and provided positive FY2026 EPS guidance.
Prime Editing and CRISPR Market Set for Explosive Growth at 24.1%
The global Prime Editing and CRISPR Market is projected to grow at a CAGR of 24.1% between 2024 and 2031, driven by advancements in gene editing therapies, expanding applications in various diseases, and increased investments. North America leads the market with a 34.5% share, while Asia Pacific shows the fastest growth. Key players include Beam Therapeutics, GenScript Biotech, and Thermo Fisher Scientific, with ongoing developments in therapeutic applications, agricultural innovation, and strategic acquisitions shaping the industry.
